Suppliers and service providers at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
111 suppliers and service providers are at ASH 2026 — 2 presentations on the program and 105 with a booth in the exhibit hall. Most represented: Answers in CME (1 on the program), PRIME Education (1 on the program), Sarah Cannon Research Institute (1 on the program). 108 of them have their own page in this guide. As of Sep 27, 2026.
Topic
Top represented
Showing 1–15 of 111 organizations
| Organization | ASH 2026 Attendance |
|---|---|
Accredited medical education company producing continuing education programs for clinicians. | Symposium Fri Dec 11 7:00pm–10:00pm From Evidence to Action in MPNs: Transforming Challenges to Opportunities in PV and ET Patients Treatment options for polycythemia vera and essential thrombocythemia after first-line therapy fails, including new targeted drugs for patients with unmet needs. Symposium Fri Dec 11 3:00pm–6:00pm Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence Tailoring four-drug frontline regimens for newly diagnosed myeloma using residual disease testing, transplant criteria, and new ways of giving treatment. |
Accredited continuing medical education company producing programs for oncology and hematology care teams. | Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium Fri Dec 11 3:00pm–6:00pm Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum Getting relapsed lymphoma patients to CAR-T sooner, with earlier referral, bridging therapy, sequencing choices, and management of immune and nerve toxicities. |
Sarah Cannon Research Institute Nashville, TN | |
Oncology research organization running cancer clinical trials in community settings for more than 30 years. | Booth Exhibiting at Booth 2316 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. |
MLL Munich Leukemia Laboratory Munich, Germany | |
Specialized laboratory in Munich diagnosing leukemias and lymphomas with cytomorphology, flow cytometry, cytogenetics and molecular genetics. | |
NV NYBC Ventures | |
Corporate venture investment arm of New York Blood Center Enterprises. | |
PeerView Institute for Medical Education New York, NY | |
Accredited continuing medical education provider producing live and online programs for clinicians, including hematology and oncology symposia. | Symposium Fri Dec 11 7:00pm–10:00pm Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms CAR-T as standard lymphoma care and what comes next, including dual-target, faster-manufactured, and in vivo versions that could widen patient access. Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. |
Decera Clinical Education Reston, VA | |
Accredited medical education company (Clinical Education Alliance) running clinician education programs and satellite symposia, with data and market-research services. | Booth Exhibiting at Booth 2123 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. |
Jointly accredited provider of continuing education for physicians, pharmacists, nurses and other members of the healthcare team. | Symposium Fri Dec 11 7:00am–10:00am MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum Managing myelodysplastic neoplasms across their spectrum, from clonal hematopoiesis and lower- and higher-risk disease to overlap syndromes and leukemia. |
Adaptive Biotechnologies Seattle, WA | |
Immune-sequencing company behind the clonoSEQ minimal residual disease test; also develops immune-based diagnostics and therapeutics. | Booth Exhibiting at Booth 3629 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
aetherAI Taipei, Taiwan | |
Taiwanese digital pathology company building AI tools that support image-based diagnosis. | Booth Exhibiting at Booth 805 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Agilent Technologies Santa Clara, CA | |
Life sciences and diagnostics company supplying laboratory instruments, software and consumables to customers in over 100 countries. | Booth Exhibiting at Booth 306 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Allucent Cary, NC | |
Contract research organization running clinical trials for small and mid-sized biotechs, with hematology, rare blood disorder and cell and gene therapy expertise. | Booth Exhibiting at Booth 707 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
AplusA Lyon, France | |
Healthcare market research company offering syndicated real-world patient databases, with a strong focus on hematologic cancers and blood disorders. | Booth Exhibiting at Booth 2957 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Aptitude Health Atlanta, GA | |
Consultancy helping life science companies develop and commercialize oncology and hematology products, drawing on networks of disease experts and clinicians. | Booth Exhibiting at Booth 2516 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Arima Genomics Carlsbad, CA | |
Genomics company whose CLIA-certified Aventa lab offers a whole-genome lymphoma test detecting B- and T-cell lymphoma rearrangements in one assay. | Booth Exhibiting at Booth 2959 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Instantly find 20 buyers from suppliers and service providers
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction